Leqembi Safety: Label Has Distinct MRI Schedule But Follows Aduhelm On ARIA Management

With the second amyloid-targeting antibody for treatment of Alzheimer’s, US FDA opted for a class-wide approach to management of amyloid-related imaging abnormalities, but with a product-specific MRI monitoring schedule that differs from that of Aduhelm.

Drug Review Profile: Leqembi
Leqembi and Aduhelm carry different schedules for MRI monitoring for ARIA. • Source: Pink Sheet/Shutterstock

When the US Food and Drug Administration granted accelerated approval to Eisai Co., Ltd. and Biogen, Inc.’s Leqembi (lecanemab-irmb), making it the second amyloid-targeting antibody indicated for Alzheimer’s disease, the agency opted for a class-wide approach to labeling on management of amyloid-related imaging abnormalities, albeit with a product-specific MRI monitoring schedule.

The agency also looked to the labeling of the first comer, Biogen/Eisai’s Aduhelm (aducanumab-avwa), for recommendations regarding continued dosing with lecanemab following resolution of mild ARIA or cerebral hemorrhage.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Drug Review Profiles

Potency Assay Issues Delayed US FDA Approval Of Mesoblast’s Ryoncil For Years

 
• By 

The company’s failure to show its potency assays measured attributes directly related to the mesenchymal stromal cell product’s therapeutic effect highlights the importance of a robust CMC program for complex cell therapies.

Mesoblast’s Ryoncil: US FDA Changed Its Mind On Need For A Randomized Trial

 
• By 

Agency staff repeatedly said the BLA based on a single-arm study in 55 patients lacked substantial evidence of effectiveness in steroid-refractory acute graft-versus-host disease and a randomized trial was needed, but changed course “based on additional consideration” after a second CRL.

Ryoncil Chronology: Three Review Cycles, Two CRLs, One Dispute Resolution Request

 
• By 

The Pink Sheet’s Drug Review Profile looks at the timeline for the clinical development and US FDA review of Mesoblast’s remestemcel for graft-versus-host disease.

Testosterone, TRAVERSE, And A Label Change 15 Years In The Making

 

The Pink Sheet drug review profile investigates the long and rigorous process behind the FDA’s recent relaxation of the cardiovascular safety warning for testosterone products.

More from Product Reviews